Table 2.

Multiple Cox regression model using NLRR3 expression and dichotomous factors of MYCN expression, Miz-1 expression, age, MYCN amplification, stage, TrkA expression, and origin (n = 87)

ModelFactorPHR (95% CI)
Univariate analysis
 ANLRR3 mRNA expression (high vs. low)0.0041a0.291 (0.125–0.678)
 BMYCN mRNA expression (high vs. low)<0.0001a5.050 (2.450–10.40)
 CMiz-1 mRNA expression (high vs. low)0.0021a0.212 (0.080–0.561)
 DAge (≥1 vs. <1 y)0.0161a0.309 (0.119–0.803)
 EMYCN amplification (single copy vs. amplified)<0.0001a4.628 (2.281–9.387)
 FStage (1,2,4s vs. 3,4)0.0010a12.66 (3.023–53.09)
 GTrkA expression (high vs. low)0.0070a7.180 (1.714–30.07)
 HOrigin (adrenal gland vs. others)0.0480a2.125 (1.005–4.491)
Multivariate analysis
 ANLRR3 mRNA expression (high vs. low)0.0610.424 (0.172–1.041)
MYCN mRNA expression (high vs. low)0.0011a3.707 (1.735–7.921)
 BNLRR3 mRNA expression (high vs. low)0.1510.503 (0.198–1.283)
Miz-1 mRNA expression (high vs. low)0.0301a0.304 (0.104–0.893)
 CNLRR3 mRNA expression (high vs. low)0.0150a0.347 (0.148–0.814)
Age (≥1 vs. <1 y)0.0530.384 (0.146–1.013)
 DNLRR3 mRNA expression (high vs. low)0.1210.545 (0.253–1.173)
MYCN amplification (single copy vs. amplified)0.0001a3.940 (1.893–8.203)
 ENLRR3 mRNA expression (high vs. low)0.1040.493 (0.210–1.156)
Stage (1, 2, 4s vs. 3, 4)0.0020a10.108 (2.359–43.309)
 FNLRR3 mRNA expression (high vs. low)0.0212a0.361 (0.152–0.863)
TrkA expression (high vs. low)0.0163a5.892 (1.395–24.901)
 GNLRR3 mRNA expression (high vs. low)0.0070a0.308 (0.132–0.720)
Origin (adrenal gland vs. others)0.0841.937 (0.914–4.104)

NOTE: All variables with 2 categories. HR shows the relative risk of death of first category relative to the second.